Catharina Ziekenhuis Stichting — Clinical Trial Site

134 Registered trials

67 Currently recruiting

Organisation

Catharina Ziekenhuis Stichting

Location

Eindhoven, Netherlands

Identifier

ORG-100021670

Address

Michelangelolaan 2, 5623 EJ, Netherlands

Departments

#2920:Cardiology
031005: Endocrinology
5004: Pulmonology
Algemene Chirurgie
Cardiologie
Cardiology
Catharina
Catharina Ziekenhuis
Catherina Cancer Institute
Clinical Pharmacy
Department of Lung Medicine
Department of Medical Oncology
Department of Oncology
Department of Pulmonology
Department of Surgery
Department R&D Cardiology
Dermatology
Emergency Department
gastroenterology
Gastroenterology and Hepatology
General Surgery
Gynaecologic Oncology
Gynaecologie
Gynaecologische Oncologie
Gynaecology
Gynecology and obstetrics
Hemato-oncology
Hematology
Intensive care
Internal Medicine / Dialysis
Internal Oncology
interne geneeskunde
interne geneeskunde/hematologie
Longgeneeskunde
Lungresearch
MDL
Medical Oncology
Medische Oncologie
N/A
Nefrologie
Neurology
Obstetrics & Gynecology
Oncologie
Oncology
Ostetrics & Gynaecology
Paediatric Gastroenterology
Paediatrics
Pneumology
Pulmonary Science
Pulmonology
R&D Heart Centre
Radiotherapy
Reproductive medicine and gynecology
Surgery
TBC
Urology
Vascular Surgery
Verloskunde & Gynaecologie

Clinical trials at this site (134)

Search interface

SAFEST Not authorised

2022-502059-79-00 Ischemic stroke or transient ischemic attack 6
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Perioperative versus adjuvant FOLFIRINOX for resectable pancreatic cancer: the PREOPANC-3 study Pending

2024-510617-15-00 Non-metastatic resectable pancreatic cancer 5
Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with… Pending

2024-512318-16-00 Patients with colorectal peritoneal metastases with a P 4
Avelumab Short Maintenance Trial Pending

2024-512975-11-01 urothelial cancer 11
Ultrasound-guided Radiofrequency Ablation versus radioactive Iodine as treatment for Hyperthyroidism caused by Solitary Autonomous Thyroid N… Pending

2024-515602-34-01 Hyperactive thyroid nodules 11
Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases – a phase… Pending

2024-517152-34-00 Irresectable peritoneal metastases of colorectal cancer 4
Chemo-immunotherapy before and after surgery for peritoneal metastases of large bowel cancer. Pending

2024-518570-13-00 Resectable peritoneal metastases of a colorectal origin 10
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults with Non-cystic Fibrosis Bronchiectasis (NCFB) Pending

2024-518821-13-00 Non-cystic Fibrosis Bronchiectasis 4
PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Pending

2025-522883-34-00 Metastatic cervical cancer 6
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
MERCURE study: MEthotrexate in ReCurrent dVIN Pending

2025-524373-17-00 dVIN caused by Lichen Sclerosus 6
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Rectal cancer 5 2025-12-10
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting

2024-512753-24-00 Acute Myeloid Leukemia (AML) 5 2025-08-05
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo… Recruiting

2024-517410-15-01 Rectal cancer 5 2025-01-14
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney D… Recruiting

2025-523123-22-00 Chronic Kidney Disease 5 2026-05-07
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial Recruiting

2025-521316-19-00 Urolithiasis 6 2026-04-20
Peri-operative intraperitoneal irinotecan and systemic FLOT in the curative treatment of gastric cancer and gastroesophageal junction cancer… Recruiting

2025-522864-34-00 Gastric cancer 3 2026-03-30
Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait A… Recruiting

2025-523692-39-00 locally advanced rectal cancer 5 2026-03-11